Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vopikitug
- Development stage
- Phase 1
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Vopikitug (RG6292, RO7296682)** is an afucosylated human IgG1 monoclonal antibody developed by Roche that targets **CD25 (IL-2 receptor alpha subunit)** on regulatory T cells (Tregs). Engineered to selectively deplete Tregs via enhanced antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis while preserving IL-2 signaling on effector T cells, it aims to enhance antitumor immunity without broad immunosuppression. Administered intravenously, it demonstrated dose-dependent peripheral and intratumoral Treg depletion in phase 1 trials for advanced solid tumors, both as monotherapy and in combination with atezolizumab, but showed insufficient clinical efficacy leading to trial terminations. Preclinical data also supported potential in acute myeloid leukemia (AML), particularly in CD25-expressing leukemic stem cells.
- Other names
- vopikituganti-CD25 monoclonal antibodyanti-CD-25 monoclonal antibodyanti-CD 25 monoclonal antibody
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)
Beyond the preview
Go deeper on vopikitug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vopikitug.